U.S. stocks movement: Novartis shares fall more than 2% pre-market as Q1 net sales decline year-on-year for the first time in two years

格隆汇2026/04/28 09:01

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Finance April 28th | Novartis (NVS.US) fell 2.37% in pre-market trading, at $140.77. According to reports, Novartis' first quarter 2026 profit came in lower than analysts' expectations and sales unexpectedly declined, as some of its best-selling drugs faced intense competition from generics. The financial report shows Novartis’ net sales for the first quarter were $13.113 billion, down 1% year-on-year, marking the first year-on-year decline in nearly two years. Core operating profit fell 12% year-on-year to $4.897 billion, missing analysts’ forecasts of $5.18 billion. Core earnings per share stood at $1.99, down 13% year-on-year. (Golden Finance)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amid ongoing implementation of industry policies, Jiayin Tech has adapted to changing circumstances by accelerating strategic adjustments to its business structure, continuously optimizing its client base and business structure in areas such as customer acquisition, risk control, and operations. By the end of Q2, the company's cash and cash equivalents had risen significantly to 504 million RMB, strengthening its ability to weather industry cycles and ensuring solid development in the future.

智通财经•2026/08/28 10:26